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Raloxifene is a selective estrogen receptor modulator typically prescribed for the 
prevention/treatment of osteoporosis in postmenopausal women. Although raloxifene 
is known to have anti-inflammatory properties, its effects on human neutrophils, the 
primary phagocytic leukocytes of the immune system, remain poorly understood. Here, 
through a screen of pharmacologically active small molecules, we find that raloxifene 
prevents neutrophil cell death in response to the classical activator phorbol 12-myristate 
13-acetate (PMA), a compound known to induce formation of DNA-based neutrophil 
extracellular traps (NETs). Inhibition of PMA-induced NET production by raloxifene was 
confirmed using quantitative and imaging-based assays. Human neutrophils from both 
male and female donors express the nuclear estrogen receptors ERα and ERβ, known 
targets of raloxifene. Similar to raloxifene, selective antagonists of these receptors 
inhibit PMA-induced NET production. Furthermore, raloxifene inhibited PMA-induced 
ERK phosphorylation, but not reactive oxygen species production, pathways known to 
be key modulators of NET production. Finally, we found that raloxifene inhibited PMA-
induced, NET-based killing of the leading human bacterial pathogen, methicillin-resistant 
Staphylococcus aureus. Our results reveal that raloxifene is a potent modulator of 
neutrophil function and NET production.
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inTrODUcTiOn
Neutrophil extracellular traps (NETs), first described in 2004 (1), are DNA-based structures deco-
rated with antibacterial components (e.g., histones, antimicrobial peptides, and myeloperoxidase) 
that form during a specialized cell death pathway (NETosis) to ensnare and kill pathogens. Since 
their initial discovery, NETs have been shown to play an important role in host defense; however, 
the molecular mechanisms that control NET production remain a topic of active investigation. 
Although NET production is typically driven in concert with the generation of reactive oxygen 
species (ROS) and activation of PKC, additional pathways that facilitate NET production (e.g., 
ERK activation, histone citrullination, and intracellular ceramide accumulation) have been identi-
fied in recent years (2–4). Identification of novel pathways that modulate NETosis could reveal 
new therapeutic targets to enhance antibacterial innate immunity or inhibit aberrant neutrophil-
mediated inflammatory responses.
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Recently, we demonstrated that tamoxifen, an estrogen 
receptor modulator classically described as an estrogen receptor 
antagonist, is a potent NET inducer (4). Our results indicated 
that tamoxifen-induced NET production is largely driven by an 
accumulation of intracellular ceramide resulting from inhibi-
tion of glucosylceramide synthase. This finding prompted us to 
investigate whether other selective estrogen receptor modulators 
(SERMs) with pharmacological properties distinct from tamox-
ifen may also modulate neutrophil function/NET production. Of 
immediate interest was raloxifene, an FDA-approved compound 
typically prescribed for the prevention or treatment of osteoporo-
sis in postmenopausal women (5). Similar to tamoxifen, the most 
well-characterized pharmacological targets of raloxifene are the 
nuclear estrogen receptors ERα and ERβ (6). Although raloxifene 
has been described to exhibit potent anti-inflammatory effects 
(7), our understanding of how it affects neutrophil function 
remains limited (8), with no studies having directly assessed its 
effects on human neutrophils. Intriguingly, however, raloxifene 
treatment reduces plasma neutrophil myeloperoxidase levels 
in vivo (9). Because myeloperoxidase is released into the plasma 
following NET induction (10), this association suggested that 
raloxifene may inhibit NET production. Here, we provide evi-
dence that raloxifene prevents neutrophil cell death in response to 
treatment with the NET inducer phorbol 12-myristate 13-acetate 
(PMA). Building on these results, we use both quantitative and 
imaging-based approaches to define the effects of raloxifene on 




Raloxifene hydrochloride, MPP dihydrochloride, and PHTTP 
were purchased from Tocris Bioscience (Bristol, UK). PMA, mic-
rococcal nuclease from Staphylococcus aureus, the small molecule 
library used for screening and all other compounds were obtained 
from Sigma-Aldrich (St. Louis, MO, USA).
cell Viability screen
An image-based screen, described in detail in Ref. (2), was used in 
conjunction with the Sigma LOPAC (Library of Pharmacologically 
Active Compounds; Sigma-Aldrich, St. Louis, MO, USA) library 
of ~1280 pharmacologically active small molecules. Following 
exposure to compounds from this library (each at a final concen-
tration of 100 μM), cell viability in response to 4-h PMA treatment 
was quantified by fixing cells with 2% paraformaldehyde, staining 
nuclei with the fluorescent DNA stain Sytox Green (2 μM; Life 
Technologies, Carlsbad, CA, USA), and imaging using an Ascent 
Fluoroskan MTP reader (Thermo Scientific).
neutrophil isolation
Venous blood was collected from healthy volunteers according 
to an approved protocol. Heparin was used as an anticoagulant. 
Neutrophils were isolated using Polymorphprep density gradi-




To visualize NETs, cells were seeded in Nunc Lab-Tek II 
Chambered Coverglass slides (Thermo Fisher, Waltham, MA, 
USA) at a density of 2 × 105 cells/well. Following incubation with 
indicated antagonist compounds, NET production was induced 
via addition of 25 nM PMA prior to a 2-h incubation at 37°C 
with 5% CO2. Cells were fixed by addition of paraformaldehyde 
(4% final) for 10 min at 24°C. Following three washes with PBS, 
neutrophils were permeabilized via incubation in Triton X-100 
solution (0.1%) for 10  min at 24°C. After an additional three 
washes with PBS, DNA was stained with 2 μM Sytox Green (Life 
Technologies, Carlsbad, CA, USA) for 10 min at 24°C; slides were 
then washed a final three times with PBS prior to imaging using a 
Zeiss AxioObserver D1 microscope equipped with an LD A-Plan 
20X/0.35 Ph1 objective (Carl Zeiss AG, Oberkochen, Germany).
Imaging of intracellular ceramide was performed by permea-
bilizing cells with 0.25% Triton X-100 prior to fixation with para-
formaldehyde, blocking with PBS containing 2% bovine serum 
albumin (2% PBS-BSA), and 2% donkey serum for 1 h. Cells were 
subsequently incubated for 1  h with mouse anti-ceramide pri-
mary antibody (1:300 in 2% PBS-BSA; Sigma-Aldrich, St. Louis, 
MO, USA) and 45 min (protected from light) with Alexa Fluor 
488 donkey anti-mouse IgG secondary antibody (1:500 in 2% 
PBS-BSA; Life Technologies, Carlsbad, CA, USA). Representative 
images shown were collected the Zeiss AxioObserver D1 
microscope and objective described above, with exposure and 
gain settings kept consistent during collection of control and 
raloxifene-treated images.
Picogreen neT Quantification assay
All incubations were performed at 37°C and 5% CO2 unless 
otherwise noted. Isolated neutrophils were plated on 96-well 
tissue culture plates at 2 ×  105  cells/well. Cells were pretreated 
with estrogen receptor antagonists (e.g., raloxifene) for 30 min, 
then incubated an additional 2 h with PMA (25 nM) to induce 
NET production. Micrococcal nuclease was then added at a final 
concentration of 500  mU/ml for 10  min to allow digestion of 
extracellular DNA. Following addition of 5  mM EDTA, plates 
were centrifuged at 200  ×  g for 8  min; supernatant samples 
(100 μl) were then collected and transferred to a 96-well plate. 
DNA was quantified using a Quant-iT PicoGreen® dsDNA Assay 
Kit from Life Technologies (Carlsbad, CA, USA).
Quantification of estrogen receptor 
expression
Freshly isolated neutrophils were harvested and 1 ×  106  cells 
resuspended in TRIzol Reagent (Thermo Fisher Scientific, 
Waltham, MA, USA). Total RNA was extracted using a Zymo 
Research Direct-zol RNA kit (Irvine, CA, USA) following the 
manufacturer’s protocol (including DNAse treatment). Following 
quantification of RNA using a Thermo Fisher Scientific Nanodrop 
Spectrophotometer (Waltham, MA, USA), quantitative PCR was 
performed on an ABI 7000 platform using USB® Veriquest™ 
Probe One-Step qRT-PCR Master Mix (2×). Predesigned human 
TaqMan® Gene Expression Assays (Life Technologies, Carlsbad, 
AB
C
FigUre 1 | raloxifene inhibits PMa-induced neT production. (a) A 
plate reader-based live–dead screening assay was used to assess the affects 
of raloxifene on PMA-induced cell death. (B) PMA-induced NET production 
was quantified in cells pre-incubated with raloxifene at the indicated 
concentrations; PicoGreen DNA dye was used to measure extracellular DNA 
(NET production expressed as a percent of PMA-only control; n = 5). (c) 
Visualization of NET production by control (CTL) or PMA-induced NETs in the 
presence or absence of raloxifene (3 μM). DNA/NETs stained with Sytox 
Green. Data shown are expressed as mean values ± SE of the indicated 
number of biological replicates (each performed in triplicate). Where 
applicable, results were analyzed by one-way ANOVA.
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CA, USA) were used to probe for expression of ESRRG, ESR2, 
and GAPDH. An equal input of total RNA was used for each 
assay.
Transwell chemotaxis assay
Neutrophils, pre-incubated for 20  min at 37°C in HBSS alone 
or HBSS with 10 μM raloxifene, were seeded in 6-mm transwell 
permeable supports (3-μm pore size; Corning Inc., Corning, NY, 
USA) that were placed in 24-well plates; lower chambers contained 
either HBSS alone or 100 nM f-Met-Leu-Phe (fMLP). Following a 
45-min incubation at 37°C, inserts were removed, and cells were 
lysed by addition of Triton X-100 (0.1% final, 10 min, 24°C). To 
determine the relative levels of migration to the lower well, the 
colorimetric elastase substrate N-methoxysuccinyl-Ala-Ala-Pro-
Val p-nitroanilide was added to lysed cell samples (10 mM final); 
after a 30-min incubation at 24°C, absorbance at 405  nm was 
measured using a SpectraMAX Gemini EM fluorescence reader 
(Molecular Devices, Sunnyvale, CA, USA).
Phagocytosis assay
Following a 30-min incubation at 37°C in the presence or absence 
of 10  μM raloxifene, neutrophils were combined in a 96-well 
plate (2 × 105 cells/well) with pHrodo Red S. aureus Bioparticles 
(Life Technologies, Carlsbad, CA, USA) as specified by the 
manufacturer. Plates were incubated at 37°C, and phagocytosis 
was assessed by measuring fluorescence intensity (560 nm excita-
tion, 585 nm emission) at 15 min intervals using a SpectraMAX 
Gemini EM fluorescence reader (Molecular Devices, Sunnyvale, 
CA, USA).
rOs Production assays
Neutrophils were incubated in HBSS supplemented with 10 mM 
2′,7′-dichlorofluorescein diacetate (DCFDA) for 20 min at 37°C 
with gentle agitation. Neutrophils were then centrifuged at 
400 ×  g for 5  min, washed with HBSS, and centrifuged again 
using the same settings before being counted and resuspended in 
HBSS at a concentration of 5 × 106 cells/ml. Samples (100 μl) of 
cell suspension were then added to a 96-well plate (5 × 105 cells/
well) and incubated with HBSS or raloxifene for 30  min prior 
to addition of PMA. Fluorescence intensity (485 nm excitation, 
530  nm emission) was measured at 15-min intervals using a 
SpectraMAX Gemini EM fluorescence reader over 2 h; between 
reads, plates were incubated at 37°C while protected from light.
Total/Phospho-erK elisa
Relative levels of total/phospho-ERK were determined using 
InstantOne ELISA kits (eBiosciences, San Diego, CA, USA) 
according to the manufacturer’s protocol, with minor modifica-
tions (11). Total/phospho ERK was quantified following PMA 
stimulation (25  nM) for 45  min in the presence or absence of 
raloxifene (10 μM).
neT Killing assay
Neutrophils suspended in serum-free RPMI (SF-RPMI) were 
added to 48-well plates at a density of 4 × 105 cells/well. SF-RPMI 
or raloxifene (10 μM final) was added to applicable wells, and 
cells were incubated for 30 min at 37°C with 5% CO2 (identical 
wells containing no neutrophils were also prepared). Following 
addition of PMA to applicable wells, cells were incubated for a 
further 4 h at 37°C with 5% CO2. Overnight cultures of USA300 
MRSA (strain UAMS 1182) bacteria were resuspended in RPMI 
containing 10% 70°C heat-inactivated fetal bovine serum (FBS) 
to achieve a density of 8 × 105 colony forming units (CFUs)/ml. 
Fifty microliters of bacterial suspension were added to each well, 
resulting in a 2% final concentration of FBS and a multiplicity of 
infection (MOI) of 0.1. Following a centrifugation at 1600 rpm 
for 5  min, mixed neutrophil/bacterial cultures were incubated 
for 15 min at 37°C with 5% CO2. Samples from each well were 
then collected, serially diluted in sterile H2O, and plated on Todd 
Hewitt Agar for enumeration of CFUs.
statistical analysis
All statistical analyses described in the figure legends were per-
formed using GraphPad Prism version 7.0.
resUlTs
raloxifene inhibits PMa-induced 
neT Production
An image-based cell viability screen (2) using the fluorescent 
DNA dye Sytox Green identified raloxifene as one of the small 
molecules from the ~1200 pharmacologically active known 
compounds tested to have enhanced the survival of neutrophils 
when exposed to PMA, a potent NET inducer (Figure 1A), sug-
gesting that raloxifene treatment may inhibit NET production. 
A B
C D
FigUre 2 | raloxifene does not affect neutrophil chemotaxis or phagocytosis but reduces intracellular ceramide. (a) Transwell chemotaxis assays were 
used to quantify neutrophil migration in a gradient of the chemottractant fMLP (100 nM) in the presence or absence of 10 μM raloxifene (n = 3). (B) Neutrophils were 
incubated with pH-sensitive S. aureus-labeled bioparticles in the presence or absence of 10 μM raloxifene (n = 3). (c) An immunostaining approach was used to 
visualize ceramide accumulation in untreated control (CTL) or raloxifene-treated (RX; 10) neutrophils (45 min incubation); representative images from three separate 
experiments are shown. (D) Mean fluorescence intensity (MFI) values were collected using region of interest analysis to quantify relative ceramide levels in control 
and 10 μM raloxifene-treated neutrophils. Results shown represent average MFI values for 96–193 cells imaged using identical settings in three separate 
experiments. Where applicable, results were analyzed by one-way ANOVA and post-hoc Dunnett’s test or Student’s t-test. ***P < 0.001 vs. control values.
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To directly assess the effect of raloxifene on NET production, 
we quantified release of DNA using the fluorescent DNA dye 
PicoGreen, finding a concentration-dependent inhibition of 
PMA-induced NET production by the drug (Figure 1B). These 
results were confirmed via fluorescence microscopy of SYTOX 
Green-stained cells, which revealed a reduction in the number 
of NET-positive cells and an increase in the number of intact, 
condensed nuclei (Figure 1C).
raloxifene Does not affect neutrophil 
chemotaxis or Phagocytosis but reduces 
intracellular ceramide
We previously demonstrated that tamoxifen, in addition to 
stimulating NET production, enhances both chemotaxis in a 
chemoattractant gradient and phagocytosis of bacteria-labeled 
bioparticles (4). Tamoxifen treatment also increases intracellular 
ceramide levels in neutrophils via inhibition of glucosylceramide 
synthase, a key enzyme in the sphingolipid synthesis pathway 
that converts ceramide to glucosylceramide. Tamoxifen-induced 
NET production is dependent on this increase of intracellular 
ceramide (4). In contrast to our observations with tamoxifen, 
we found that raloxifene had no statistically significant effect 
on either chemotaxis in a gradient of the chemoattractant fMLP 
(Figure  2A) or phagocytosis of S. aureus-labeled bioparticles 
(Figure 2B). Furthermore, immunostaining of raloxifene-treated 
neutrophils revealed that, in contrast to tamoxifen, raloxifene 
reduces intracellular ceramide levels (Figures 2C,D).
selective estrogen receptor antagonists 
inhibit PMa-induced neT Production
Quantitative PCR-based analysis of ERα and ERβ expression 
in neutrophils from 12 healthy donors (6 male and 6 female) 
revealed that circulating neutrophils express both nuclear recep-
tors (Figure 3A). Fluorescence-based quantification of NET pro-
duction indicated that the selective estrogen receptor antagonists 
MPP (ERα inhibitor) and PHTPP (ERβ inhibitor) mimicked the 
raloxifene-mediated inhibition of PMA-induced NET produc-
tion (Figure 3B). Imaging of SYTOX Green-stained cells revealed 
some residual NET production by neutrophils pre-incubated 
with MPP and PHTPP, suggesting the potential involvement of 
multiple estrogen receptors in raloxifene-mediated inhibition of 
NETosis (Figure 3C).
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raloxifene inhibits PMa-induced erK 
Phosphorylation but not PMa-induced 
rOs Production
Reactive oxygen species production was quantified using the 
membrane-permeable fluorescent ROS probe 2′,7′-dichloro-
fluorescein diacetate (DCFDA). Although PMA-induced NET 
production is known to be ROS dependent (1), raloxifene did 
not inhibit PMA-induced ROS production (Figures  4A,B). 
However, ELISA-based quantification of ERK phosphorylation 
revealed that raloxifene significantly inhibited PMA-induced 
ERK activation (Figure  4C), a critical signaling event that has 
been shown to play a role in NET production (2).
raloxifene inhibits neT-Mediated Killing 
of Methicillin-resistant Staphylococcus 
aureus
To determine whether raloxifene affects NET-based bactericidal 
activity of neutrophils, we performed a NET-based killing assay 
in which neutrophils were pre-stimulated with PMA to induce 
NET production prior to challenge with methicillin-resistant 
A B
C
FigUre 3 | selective antagonists of erα and erβ inhibit PMa-induced neT production. (a) Quantitative PCR was used to measure ERα and ERβ gene 
expression in neutrophils from 12 healthy donors [6 males (M), 6 females (F)]. Data expressed as ΔCt values relative to GAPDH. (B) PMA-induced NET production 
was quantified in cells pre-incubated with MPP (selective ERα antagonist) or PHTPP (selective ERβ antagonist) at the indicated concentrations; PicoGreen DNA dye 
was used to measure extracellular DNA (NET production expressed as a percent of PMA-only control; n = 5). (c) Visualization of PMA-induced NET production in 
cells pre-incubated with MPP or PHTPP. DNA/NETs stained with Sytox Green. Data shown are expressed as mean values ± SE of the indicated number of biological 
replicates (each performed in triplicate). Where applicable, results were analyzed by one-way ANOVA and post hoc Newman–Keuls test.
A B C
FigUre 4 | raloxifene inhibits PMa-induced erK phosphorylation, but not PMa-induced rOs production. ROS production in control and 25 nM 
PMA-treated neutrophils in the presence/absence of raloxifene (10 μM) was quantified over time (a) and at 2 h (B) using the cell-permeable fluorescent ROS probe 
DCFDA (n = 3). (c) PMA-induced ERK phosphorylation in the presence/absence of 10 μM raloxifene was quantified using total/phospho ELISAs (n = 4). Data 
shown are expressed as mean values ± SE of the indicated number of biological replicates (each performed in duplicate or triplicate). Where applicable, results were 
analyzed by one-way ANOVA and post hoc Newman–Keuls test. *P < 0.05, ***P < 0.001 vs. control values.
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DiscUssiOn/cOnclUsiOn
Here, we show evidence that the SERM raloxifene inhibits 
PMA-induced NET production. Unlike tamoxifen, an estrogen 
receptor modulator that induces NET production (4), raloxifene 
reduces intracellular ceramide levels. Neutrophils from both male 
and female donors express the nuclear estrogen receptors ERα 
and ERβ, the best characterized targets of raloxifene. Selective 
antagonists of either receptor inhibited PMA-induced NETosis, 
suggesting that raloxifene may act through multiple receptors to 
inhibit NET production, and further indicating that tamoxifen-
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FigUre 5 | raloxifene inhibits neT-mediated killing of methicillin-
resistant Staphylococcus aureus. Neutrophil killing of USA300 MRSA 
was quantified in a NET-based killing assay. Control (CTL) represents bacteria 
exposed to unstimulated neutrophils and PMA represents neutrophils treated 
with 25 nM PMA. Raloxifene (RX; 10 μM) or DNase (7.5 U/ml) were added 
30 min prior or 3.5 h following addition of PMA, respectively (n = 3). Data 
shown are expressed as mean values ± SE of three independent 
experiments, each performed in triplicate. Results were analyzed by 
Student’s t-test. **P < 0.01 vs. control values.
receptor-independent, non-specific effects (e.g., inhibition of 
glucosylceramide synthase). We find that raloxifene inhibits 
PMA-induced ERK phosphorylation, a signal transduction event 
known to be critical for NETosis (2); thus, raloxifene likely modu-
lates NET production via regulation of ERK signaling.
Our results suggest that raloxifene may have beneficial thera-
peutic effects in contexts where excessive NETosis is undesirable 
and associated inflammatory changes cause damage to the host 
(12). NETs appear to play a role in the pathophysiology of 
rheumatoid arthritis (13); notably, raloxifene has been shown 
to exhibit significant antiarthritic properties in a murine model 
of this disease (14). The incidence of rheumatoid arthritis in 
raloxifene-treated postmenopausal women (and specifically the 
contribution of NETs to disease pathophysiology) represents an 
important area for further investigation; however, our results also 
suggest that raloxifene therapy may come at some consequence 
to patients at high risk of infection, as raloxifene inhibits NET-
mediated bacterial killing.
These findings provide new insight into the effects of raloxifene 
on neutrophil function, which at present are poorly understood. 
Such effects hold important clinical implications, given the large 
number of patients receiving this drug. Further exploration of 
the pathways mediating the anti-NETosis activity of raloxifene 
may reveal new therapeutic targets and facilitate development of 
therapies that can more selectively regulate NET production in 
appropriate physiological contexts.
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